论文部分内容阅读
[目的]探讨人附睾蛋白4(HE4)在判断卵巢癌患者预后中的价值。[方法]检测76例卵巢癌患者治疗前血清HE4和CA125水平,分析HE4水平与患者无病生存期的关系。[结果]76例患者血清HE4中位浓度为208pmol/L。血清HE4水平同卵巢癌患者病理类型及临床分期相关(P=0.014,P<0.001)。HE4低水平患者(≤208pmol/L)的无进展生存期为29.0个月,而血清HE4高水平组(>208pmol/L)为19.0个月(P=0.005)。多因素回归分析证明HE4血清水平为判断卵巢癌患者预后的独立指标(HR=1.001,95%CI:1.000～1.002;P=0.021)。[结论]血清HE4可为卵巢癌患者预后判断提供重要的临床参考依据。
[Objective] To investigate the value of human epididymis 4 (HE4) in the prognosis of ovarian cancer patients. [Methods] The serum levels of HE4 and CA125 in 76 patients with ovarian cancer before treatment were detected, and the relationship between HE4 level and disease-free survival was analyzed. [Results] The median concentration of HE4 in serum of 76 patients was 208 pmol / L. The level of serum HE4 correlated with the pathological type and clinical stage of ovarian cancer (P = 0.014, P <0.001). The progression-free survival was 29.0 months in patients with low HE4 (≤208 pmol / L) and 19.0 months (≥0.005) in the serum HE4 high-level group (> 208 pmol / L). Multivariate regression analysis demonstrated that serum HE4 level was an independent predictor of ovarian cancer prognosis (HR = 1.001, 95% CI: 1.000-1.002; P = 0.021). [Conclusion] Serum HE4 may provide important clinical reference for the prognosis judgment of ovarian cancer patients.